BCLI
Brainstorm Cell Therapeutics Inc.NASDAQHealthcare$0.86+4.32%ClosedMarket Cap: $9.5M
As of 2026-04-04
Valuation
P/E (TTM)
0.92
PEG
0.00
P/B
-0.85
P/S
0.00
EV/EBITDA
0.00
DCF Value
$-0.72
FCF Yield
-67.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
130.9%
ROA
-1441.5%
ROIC
96.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $703.0K | 7.4% | $7.7M | $18.2M | $0.98 | — |
| FY 2025 | $703.0K | 0.0% | $0.00 | $10.3M | $0.00 | — |
| Q3 2025 | $0.00 | NaN% | $-2.0M | $-2.1M | $-0.19 | — |
| Q2 2025 | $0.00 | NaN% | $-2.6M | $-2.9M | $-0.34 | — |
| Q1 2025 | $0.00 | -Infinity% | $-3.1M | $-2.9M | $-0.45 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.2M | $-3.0M | $-0.52 | — |
| FY 2024 | $0.00 | -Infinity% | $-11.7M | $11.6M | $2.19 | — |
| Q3 2024 | $0.00 | -Infinity% | $-3.0M | $-2.7M | $-0.51 | — |
| Q2 2024 | $0.00 | -Infinity% | $-3.0M | $-2.5M | $-0.54 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.5M | $-3.4M | $-0.79 | — |
| Q4 2023 | $343.0K | 80.8% | $-4.8M | $-5.6M | $-1.66 | — |
| FY 2023 | $0.00 | -Infinity% | $-21.4M | $-17.2M | $-4.48 | — |